Side effects of COVID-19 vaccination in Pakistani population: A cross sectional study

preprint OA: closed
Full text JSON View at publisher

Abstract

_OBJECTIVES:_ Data from clinical trials around the world show that the COVID-19 vaccines are effective in terms of reducing hospitalizations need for respiratory support and deaths. However, to assess common or uncommon adverse events of the COVID-19 vaccines, data from real world experiences need to be evaluated to resolve the speculations associated with the vaccines. _MATERIALS AND METHODS:_ A questionnaire based on demographic details, vaccination details, side effects experienced, the duration of side effects and COVID-19 status was administered to study participants during this cross-sectional study. _RESULTS AND DISCUSSION:_ A total of 1162 responses were collected from fully vaccinated individuals, where Sinovac was the highly administered vaccine (40%). Most of the vaccinated participants (94%) did not contract SARS-CoV-2 infection following vaccination; however, the rate of hospitalization (4.2%) and development of extreme complications (1.4%) was lower in those who contracted the disease after vaccination compared to those who contracted COVID-19 before being fully vaccinated (7.1%). The most frequent side effects of vaccination reported were moderate pain at the site of injection administration, muscle pain, headache, fever, fatigue, swelling, redness or pain at the site of injection, nausea and joint pain. Only 2% of the participants encountered extreme daily routine difficulties while most of the side effects resolved within one week (30%). _CONCLUSION:_ The present study reports mild post vaccination side effects and low incidence of SARS-CoV-2 following COVID-19 vaccination. These results may help in improving the public perception and confidence towards COVID-19 vaccination in the Pakistani population.
Full text 621 characters · extracted from oa-doi-fallback · click to expand
There is a newer version available for this {{ publicationType }}. View latest version {{ publication.field_name }} {{ publication.subfield_name }} Copyright: © {{ publicationYear }} {{ publication.presentation_authors[0].full_name + (publication.presentation_authors.length > 1 ? ' et al' : '') }}. This is an open access publication distributed under the terms of the CC BY 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Check the {{ publicationType | capitalize }} Source for copyright and license information. Listen on

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00